Since anthracyclines are clinically used to treat multiple myeloma, acute myeloid leukemia, and hepatocellular carcinoma, ABCB1 may serve as a prognostic factor for the survival probability of patients affected with these tumor types. This evidence concerns the gene ABCB1 and neoplasm.